DCM
BNTX icon

Deuterium Capital Management’s BioNTech BNTX Stock Holding History

Deuterium Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,250
Closed -$384K – 55
2022
Q1 		$384K Buy
+2,250
New +$378K 0.49% 33

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Deuterium Capital Management's BNTX Position: Q2 2022 in Review

Deuterium Capital Management sold out of BioNTech (BNTX) in Q2 2022, closing a stake of 2,250 shares — an estimated $384K sold.

Deuterium Capital Management first reported a position in BNTX in Q1 2022 and held it in 1 quarter. The position peaked at $384K in Q1 2022. 293 funds tracked by Wall St. Rank hold BNTX as of Q2 2022.

  • Deuterium Capital Management reported no remaining BioNTech position as of Q2 2022 after selling out during the quarter.
  • Deuterium Capital Management sold 2,250 BioNTech shares in Q2 2022, an estimated $384K.
  • Deuterium Capital Management first reported a position in BioNTech in Q1 2022 and held it in 1 quarter.
  • Deuterium Capital Management's BioNTech position peaked at $384K in Q1 2022.
  • 293 funds tracked by Wall St. Rank held BioNTech as of Q2 2022.

Based on Deuterium Capital Management's 13F filing for Q2 2022, filed 27 Jul 2022.